These data revealed that tumors in situ displayed unmethylated MGMT before and after vemurafenib treatment (Fig. 6A), indicating that vemurafenib therapy had no impact on the MGMT promoter methylation status of melanoma. The gene discussed is MGMT; the disease is melanoma.